Therapeutic target identification and validation for MASLD via patient transcriptome-driven in vivo genetic screening
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is rising in prevalence over the years but current treatments such as Resmetirom are inadequate as remedy for most MASLD patients. With scarce liver sources available, liver regeneration offers a more sustainable approac...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Final Year Project (FYP) |
| Language: | English |
| Published: |
Nanyang Technological University
2024
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10356/181532 |